722.57
Lilly Eli Co (LLY) 最新ニュース
Eli Lilly (LLY) Bulls Eye $1,000 Stock Price Target as GLP-1 Alpha Bandwagon Rolls On - TipRanks
Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions - Eli Lilly and Company
Was Jim Cramer Right About Eli Lilly and Company (LLY)? - Insider Monkey
UBS maintains Eli Lilly stock with $1,050 target - Investing.com
Novo Is Losing Steam. Can It Oh, Oh, Oh, Obtain New Grounding? - Investor's Business Daily
Eli Lilly : A Breakout Biotech Powerhouse With Room to Run - MarketBeat
Eli Lilly (LLY) Gains Upper Hand in Weight-Loss Drug Market | LL - GuruFocus
Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities - GlobeNewswire Inc.
Ochre Bio appoints ex- Eli Lilly and AstraZeneca VP as Non-Executive Director - Health Tech World
The weight loss war: Who is winning out between Novo-Nordisk and Eli Lilly? - Shares Magazine
‘Start a Position’ in Eli Lilly Stock (LLY), Says Jim Cramer - TipRanks
Is Eli Lilly And Company Stock Underperforming The Dow? - Barchart.com
Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer - Yahoo Finance
Lilly adds non-opioid painkiller to pipeline in $1B Siteone buyout - BioWorld MedTech
BMO reiterates Eli Lilly stock with $900 target on SiteOne deal - Investing.com
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy? - The Globe and Mail
Lilly seeks to expand pain pipeline with $1B acquisition - dailyjournal.net
Lilly to acquire biotech developing pain drugs - statnews.com
Reports: Lilly eyes Houston for new $5.9B manufacturing facility - Indianapolis Business Journal
Lilly to acquire SiteOne Therapeutics to expand pain pipeline - World Pharmaceutical Frontiers
Eli Lilly to expand pain portfolio with SiteOne acquisition - Cleanroom Technology
Jim Cramer Notes Eli Lilly (LLY) Stock is at a “Decent Level to Start a Position” - Insider Monkey
Lilly snags Peninsula non-opioid pain drug company for up to $1 billionSan Francisco Business Times - The Business Journals
Eli Lilly Commits $1B to Get Drug That Could Rival Vertex’s New Non-Opioid Pain Med - MedCity News
Lilly's Acquisition Of SiteOne Aims For Opioid AlternativesEli Lilly (NYSE:LLY) - Benzinga
Eli Lilly Targets Pain Management Opportunity with SiteOne Therapeutics Acquisition - Insider Monkey
Eli Lilly Inks $1B Deal For Non-Opioid Pain-Drug Maker - Law360
Eli Lilly (LLY) Shows Strong Options Activity Amid Share Price Rise | LLY Stock News - GuruFocus
Eli Lilly to expand pain pipeline with $1bn SiteOne buyout - Pharmaceutical Technology
Eli Lilly to buy SiteOne for $1 billion with eye on non-opioid pain drug - Reuters
Eli Lilly’s Strategic Acquisition of SiteOne Therapeutics Bolsters Pain Management Portfolio and Supports Buy Rating - TipRanks
Eli Lilly (LLY) Expands into Pain Management Through Acquisition | LLY Stock News - GuruFocus
Eli Lilly (LLY) to Acquire SiteOne Therapeutics for $1 Billion - GuruFocus
Eli Lilly expands neuroscience pipeline with $1B SiteOne acquisition - Proactive financial news
Seven top pharmas posted revenue declines in Q1. The common thread? All are US firms - Fierce Pharma
Eli Lilly To Acquire SiteOne Therapeutics For Up To $1B To Advance Pain Management Pipeline: But Retail’s Unconvinced By Stocktwits - Investing.com India
Lilly to acquire SiteOne, enhancing non-opioid pain treatment options By Investing.com - Investing.com India
Lilly to acquire SiteOne, enhancing non-opioid pain treatment options - Investing.com Australia
Eli Lilly expands pain pipeline with acquisition of SiteOne Therapeutics By Investing.com - Investing.com Nigeria
Eli Lilly expands pain pipeline with acquisition of SiteOne Therapeutics - Investing.com
Eli Lilly (LLY) to Acquire SiteOne Therapeutics in $1 Billion De - GuruFocus
Eli Lilly’s SWOT analysis: stock poised for growth amid challenges - Investing.com
Eli Lilly to acquire privately held SiteOne - Yahoo
Eli Lilly & Co. (LLY) Acquires SiteOne Therapeutics - StreetInsider
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics | Eli Lilly and Company - Eli Lilly and Company
Lilly Makes $1B Bet on Next-Generation Pain Treatment: Key Details of SiteOne Acquisition Revealed - Stock Titan
Investment Case For Eli Lilly Still Weak, Despite Novo Nordisk's Struggle (NYSE:LLY) - Seeking Alpha
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Lilly's blood drive breaks site record - reporter.net
Here's How the Pharmaceutical Import Tariffs Could Affect Eli Lilly - AOL.com
Eli Lilly (LLY) Considers New $5.9 Billion Plant in Houston, Texas - TipRanks
Prurigo Nodularis Market - GlobeNewswire Inc.
Eli Lilly (LLY) Faces Lowered Market Forecast for Anti-Obesity D - GuruFocus
Eli Lilly & Co (LLY) Gets a Buy from Bank of America Securities - The Globe and Mail
Is Eli Lilly Stock A Sell After Novo Nordisk Wins An Unexpected Obesity Edge? - Investor's Business Daily
Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - The Globe and Mail
With short film, Eli Lilly is Seeking to transform itself as a drugmaker - PR Week
The Zacks Analyst Blog Highlights Eli Lilly, GE Aerospace and Amgen - Yahoo Finance
Eli Lilly and Company (LLY) Gains Approval in Australia for Early Alzheimer’s Treatment - Insider Monkey
大文字化:
|
ボリューム (24 時間):